Laurus Labs advances on receiving nod for Tenofovir Disoproxil Fumarate Tablets

01 Dec 2017 Evaluate

Laurus Labs is currently trading at Rs. 538.05, up by 14.15 points or 2.70% from its previous closing of Rs. 523.90 on the BSE.

The scrip opened at Rs. 550.00 and has touched a high and low of Rs. 550.00 and Rs. 535.70 respectively. So far 14,000 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 634.00 on 12-Jun-2017 and a 52 week low of Rs. 453.00 on 26-Dec-2016.

Last one week high and low of the scrip stood at Rs. 550.00 and Rs. 514.20 respectively. The current market cap of the company is Rs. 5,715.00 crore.

The promoter and public held 30.56% and 69.44% stake in the company, respectively.

Laurus Labs has received its maiden tentative approval from United States Food and Drug Administration (USFDA) for Tenofovir Disoproxil Fumarate Tablets 300mg. Tenofovir Disoproxil Fumarate Tablets 300mg is therapeutically equivalent to VIREAD Tablets 300mg of Gilead Science (GILEAD). Tenofovir Disoproxil Fumarate Tablets 300mg is used for treatment of HIV-1 infection in adults and paediatric patients 2 years of age and older.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.


Laurus Labs Share Price

586.40 15.60 (2.73%)
27-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1861.70
Dr. Reddys Lab 1389.35
Cipla 1506.15
Lupin 2228.00
Zydus Lifesciences 972.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.